XOMA Royalty Corp. (XOMA) P/E Ratio History
Historical price-to-earnings valuation from 2009 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 5, 2026, XOMA Royalty Corp. (XOMA) trades at a price-to-earnings ratio of -16.0x, with a stock price of $26.45 and trailing twelve-month earnings per share of $1.07.
The current P/E is 122% below its 5-year average of 74.4x. Over the past five years, XOMA's P/E has ranged from a low of 7.8x to a high of 353.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, XOMA trades at a 169% discount to its sector peers. The sector includes 226 companies with P/E ratios ranging from 0.0x to 194.6x.
Relative to the broader market, XOMA trades at a notable discount to the S&P 500 median P/E of 26.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XOMA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Royalty and IP Monetization Vehicles peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $27B | 26.6 | - | -7% | |
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $773M | 38.9 | - | -83% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $38.54 | $0.76 | 50.9x | -32% | |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $17.91 | $0.57 | 31.4x | -58% |
| FY2022 Q2 | $22.28 | $0.53 | 42.0x | -44% | |
| FY2022 Q1 | $27.98 | $0.86 | 32.5x | -56% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $20.85 | $0.42 | 49.6x | -33% |
| FY2021 Q3 | $24.75 | $0.07 | 353.6x | +375% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $34.00 | $0.36 | 93.8x | +26% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $40.81 | $0.23 | 175.7x | +136% |
| FY2020 Q4 | $44.13 | $0.40 | 109.7x | +47% | |
| FY2018 Q2 | Sat Jun 30 2018 00:00:00 GM | $20.88 | $2.33 | 9.0x | -88% |
| FY2018 Q1 | Sat Mar 31 2018 00:00:00 GM | $20.23 | $2.60 | 7.8x | -90% |
| FY2017 Q4 | Sun Dec 31 2017 00:00:00 GM | $35.60 | $1.50 | 23.8x | -68% |
Average P/E for displayed period: 74.4x
See XOMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XOMA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare XOMA vs LLY
See how XOMA stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is XOMA stock overvalued or undervalued?
XOMA trades at -16.0x P/E, below its 5-year average of 74.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does XOMA's valuation compare to peers?
XOMA Royalty Corp. P/E of -16.0x compares to sector median of 23.2x. The discount suggests lower growth expectations or higher risk.
What is XOMA's PEG ratio?
XOMA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2009-2025.